Loading company…
PRODEGRE researches neurological disease mechanisms and develops drug candidates for neurological conditions.
Founded in 2023 and based in Shanghai, China, PRODEGRE researches neurological diseases and develops drugs targeting conditions such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Its peptide-guided protein knockdown platform supports this work. In February 2026, it closed Angel+ funding led by Furong Capital. The funding was intended to advance its Prodegre ATLAS™ platform and work on an a-synuclein degradation agent for Parkinson's disease.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in